Myocardial Ischemia After Coronary Sinus Reduction Stent Implantation
Launched by OSLO UNIVERSITY HOSPITAL · Sep 5, 2023
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment option for patients suffering from severe chest pain known as refractory angina, which doesn’t improve with standard medications or procedures. The researchers are looking at a device called a coronary sinus reduction stent, which is implanted in a specific part of the heart to help improve blood flow and reduce the pain and discomfort associated with angina. The main goal of the study is to see if this stent can actually improve blood flow to the heart muscle and, in turn, help patients feel better and have a better quality of life.
To participate in the trial, patients need to have coronary artery disease and experience ongoing chest pain that hasn’t been relieved by other treatments. They must also be suitable for the stent procedure and agree to follow the study guidelines. During the trial, participants will undergo tests before receiving the stent and again after six months to see how their heart function and symptoms change. Importantly, the study will ensure that the results are accurate and unbiased by using detailed imaging techniques that don’t reveal whether the stent is present during evaluations. This research could provide valuable information on new ways to help patients with refractory angina feel better.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Coronary artery disease and refractory angina
- • Clinical indication for coronary sinus reduction stent implantation
- • Written informed consent
- • Anticipated compliance with protocol
- Exclusion Criteria:
- • Ineligibility for coronary sinus reduction stent implantation
- • Lack of informed consent
- • Not expected to comply with protocol
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Øyvind H Lie
Principal Investigator
Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported